# Safety and Immunogenicity of a Cell Derived Subunit Trivalent Nonadjuvated Influenza Study Vaccine in Adults Aged 18 Years and Above

> **NCT01640314** · PHASE3 · COMPLETED · sponsor: **Novartis Vaccines** · enrollment: 126 (actual)

## Conditions studied

- Influenza

## Interventions

- **BIOLOGICAL:** Cell derived subunit trivalent nonadjuvanted vaccine

## Key facts

- **NCT ID:** NCT01640314
- **Lead sponsor:** Novartis Vaccines
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-07
- **Primary completion:** 2012-08
- **Final completion:** 2012-08
- **Target enrollment:** 126 (ACTUAL)
- **Last updated:** 2016-02-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01640314

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01640314, "Safety and Immunogenicity of a Cell Derived Subunit Trivalent Nonadjuvated Influenza Study Vaccine in Adults Aged 18 Years and Above". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT01640314. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*